Belite Bio (BLTE) Preferred Stock Liabilities (2021)

Belite Bio's (BLTE) quarterly Preferred Stock Liabilities came in at $31.8 million in Q4 2021.

Belite Bio (BLTE) Preferred Stock Liabilities (2021) Analysis & Trends

Belite Bio's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $31.8 million for Q4 2021.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $31.8 million in Q4 2021; TTM through Dec 2021 was $31.8 million, a N/A change from a year earlier, with the FY2021 full-year figure at $31.8 million, changed 0.0% from the prior year.
Preferred Stock Liabilities was little changed at $31.8 million in Q4 2021 per BLTE's latest filing.
Across five years, Preferred Stock Liabilities topped out at $31.8 million in Q4 2021 and bottomed at $31.8 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn	-

Download Data

Date	Value
Dec 31, 2021	31.81 Mn